###begin article-title 0
The nuclear receptor PPARgamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity
###end article-title 0
###begin p 1
###xml 548 549 525 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1252 1253 1198 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 483 488 <span type="species:ncbi:9606">human</span>
###xml 493 498 <span type="species:ncbi:10090">mouse</span>
###xml 1243 1248 <span type="species:ncbi:9606">human</span>
###xml 1291 1299 <span type="species:ncbi:9606">patients</span>
###xml 1515 1519 <span type="species:ncbi:10090">mice</span>
###xml 1527 1533 <span type="species:ncbi:9606">humans</span>
T helper cells secreting interleukin (IL)-17 (Th17 cells) play a crucial role in autoimmune diseases like multiple sclerosis (MS). Th17 differentiation, which is induced by a combination of transforming growth factor (TGF)-beta/IL-6 or IL-21, requires expression of the transcription factor retinoic acid receptor-related orphan receptor gammat (RORgammat). We identify the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) as a key negative regulator of human and mouse Th17 differentiation. PPARgamma activation in CD4+ T cells selectively suppressed Th17 differentiation, but not differentiation into Th1, Th2, or regulatory T cells. Control of Th17 differentiation by PPARgamma involved inhibition of TGF-beta/IL-6-induced expression of RORgammat in T cells. Pharmacologic activation of PPARgamma prevented removal of the silencing mediator for retinoid and thyroid hormone receptors corepressor from the RORgammat promoter in T cells, thus interfering with RORgammat transcription. Both T cell-specific PPARgamma knockout and endogenous ligand activation revealed the physiological role of PPARgamma for continuous T cell-intrinsic control of Th17 differentiation and development of autoimmunity. Importantly, human CD4+ T cells from healthy controls and MS patients were strongly susceptible to PPARgamma-mediated suppression of Th17 differentiation. In summary, we report a PPARgamma-mediated T cell-intrinsic molecular mechanism that selectively controls Th17 differentiation in mice and in humans and that is amenable to pharmacologic modulation. We therefore propose that PPARgamma represents a promising molecular target for specific immunointervention in Th17-mediated autoimmune diseases such as MS.
###end p 1
###begin p 2
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 292 315 292 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Harrington et al., 2005</xref>
###xml 317 334 317 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Park et al., 2005</xref>
###xml 506 527 506 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Bettelli et al., 2007</xref>
###xml 717 733 717 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Cua et al., 2003</xref>
###xml 735 754 735 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Murphy et al., 2003</xref>
###xml 756 772 756 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Yen et al., 2006</xref>
###xml 851 868 851 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Lock et al., 2002</xref>
###xml 870 890 870 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Tzartos et al., 2008</xref>
###xml 1009 1028 1006 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Ivanov et al., 2006</xref>
###xml 1030 1047 1027 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">Yang et al., 2008</xref>
###xml 1178 1197 1167 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Ivanov et al., 2006</xref>
###xml 1199 1217 1188 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Manel et al., 2008</xref>
###xml 570 575 <span type="species:ncbi:10090">mouse</span>
###xml 831 836 <span type="species:ncbi:9606">human</span>
CD4+ T helper (Th) cells differentiate into discrete subsets, which can be discriminated on the basis of their cytokine expression profiles. Besides the "classical" CD4+ T cell subsets (i.e., Th1, Th2, and regulatory T cells), a new subset characterized by secretion of IL-17 was identified (Harrington et al., 2005; Park et al., 2005). Th17 cells provide protection in certain infections, but more importantly, have been linked to development of autoimmunity, a function previously assigned to Th1 cells (Bettelli et al., 2007). Th17 cells mediate pathology in several mouse models of autoimmunity, such as experimental autoimmune encephalomyelitis (EAE), inflammatory bowel disease, and collagen-induced arthritis (Cua et al., 2003; Murphy et al., 2003; Yen et al., 2006). Recent studies have addressed the role of Th17 cells in human autoimmunity (Lock et al., 2002; Tzartos et al., 2008). Th17 differentiation critically depends on TGF-beta, together with proinflammatory cytokines such as IL-6 or IL-21 (Ivanov et al., 2006; Yang et al., 2008). The key transcription factor for Th17 differentiation is retinoic acid (RA) receptor-related orphan receptor gammat (RORgammat; Ivanov et al., 2006; Manel et al., 2008). However, little information exists on the T cell-intrinsic molecular mechanisms controlling RORgammat activity, thus contributing to control of Th17-mediated autoimmunity.
###end p 2
###begin p 3
###xml 217 218 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 242 260 234 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Klotz et al., 2007</xref>
###xml 262 283 254 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">Szatmari et al., 2007</xref>
###xml 364 382 352 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Clark et al., 2000</xref>
###xml 642 662 622 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Pascual et al., 2005</xref>
###xml 664 685 644 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Glass and Ogawa, 2006</xref>
###xml 973 993 949 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Pascual et al., 2005</xref>
###xml 995 1017 971 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Straus and Glass, 2007</xref>
###xml 1291 1309 1263 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Huang et al., 1999</xref>
###xml 1311 1333 1283 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Straus and Glass, 2007</xref>
###xml 1405 1423 1373 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Niino et al., 2001</xref>
###xml 1425 1442 1393 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Diab et al., 2002</xref>
###xml 1444 1466 1412 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Feinstein et al., 2002</xref>
We and others have previously shown that the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is a negative regulator of dendritic cell maturation and function, thereby contributing to CD4+ T cell anergy in vivo (Klotz et al., 2007; Szatmari et al., 2007). PPARgamma has also been reported to influence the function of Th cell clones (Clark et al., 2000); however, the influence of PPARgamma on Th differentiation has not yet been addressed. Upon ligand binding, PPARgamma heterodimerizes with the retinoid X receptor and binds to the PPAR response elements (PPRE) located in the promotor region of target genes (Pascual et al., 2005; Glass and Ogawa, 2006). Additionally, the antiinflammatory effects of PPARgamma are mediated by negative interference with proinflammatory cell signaling, e.g., stabilization of corepressor complexes, such as nuclear corepressor (NCoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT; Pascual et al., 2005; Straus and Glass, 2007). PPARgamma agonists include endogenous ligands such as the linoleic acid derivative 13s-hydroxyoctadecadienoic acid (HODE) produced by 12/15-lipoxygenase, as well as several synthetic agonistic ligands such as the antidiabetic thiazolidinediones, e.g., pioglitazone (PIO; Huang et al., 1999; Straus and Glass, 2007). Previous studies demonstrated a beneficial role of PPARgamma in EAE (Niino et al., 2001; Diab et al., 2002; Feinstein et al., 2002). These findings prompted us to address the question of whether PPARgamma is involved in the T cell-intrinsic control of Th17 responses.
###end p 3
###begin title 4
RESULTS AND DISCUSSION
###end title 4
###begin title 5
Control of Th17 differentiation by PPARgamma
###end title 5
###begin p 6
###xml 219 227 211 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 a</xref>
###xml 254 272 246 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Niino et al., 2001</xref>
###xml 274 291 266 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Diab et al., 2002</xref>
###xml 293 315 285 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Feinstein et al., 2002</xref>
###xml 334 335 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 519 527 511 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 b</xref>
###xml 759 764 747 752 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35-55</sub>
###xml 949 950 933 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 960 966 944 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 1050 1051 1030 1031 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1405 1413 1366 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 d</xref>
###xml 1649 1651 1594 1596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 1761 1762 1702 1703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1772 1780 1713 1721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 d</xref>
###xml 1965 1967 1898 1900 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 1977 1985 1910 1918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 d</xref>
###xml 2074 2092 2003 2021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Huang et al., 1999</xref>
###xml 2150 2158 2079 2087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 d</xref>
###xml 2328 2344 2253 2269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Vanderhoek, 1988</xref>
###xml 2615 2633 2536 2554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Huang et al., 1999</xref>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 1549 1553 <span type="species:ncbi:10090">mice</span>
###xml 1574 1578 <span type="species:ncbi:10090">mice</span>
###xml 1584 1588 <span type="species:ncbi:10090">mice</span>
We first investigated the influence of PPARgamma on the Th17 responses during MOG-induced EAE. Pharmacological activation of PPARgamma with PIO in vivo ameliorated the disease course over the entire observation period (Fig. 1 a), as previously reported (Niino et al., 2001; Diab et al., 2002; Feinstein et al., 2002). Importantly, CD4+ T cells isolated from the central nervous system (CNS) of PIO-treated EAE mice at day 17 after disease induction produced significantly less IL-17A after PMA/ionomycin restimulation (Fig. 1 b). This prompted us to investigate in more detail the influence of PPARgamma on the function of autoreactive MOG-specific T cells. We therefore determined the frequency of antigen-specific Th17 cells in the CNS by ELISpot. After MOG35-55-peptide specific stimulation of equal numbers of CNS-derived T cells, we observed a strong reduction in antigen-specific IL-17 producing, but interestingly not IFN-gamma producing, CD4+ T cells (Fig. 1). In light of these results, we next investigated the influence of PPARgamma on CD4+ Th differentiation. To focus exclusively on the effect of PPARgamma in T cells, we used stimulation with alphaCD3/alphaCD28 in the absence of antigen-presenting cells. Interestingly, PPARgamma activation by PIO selectively inhibited Th17 differentiation induced by TGF-beta and IL-6, whereas IL-12-induced Th1 differentiation was completely unaffected (Fig. 1 d; ). To obtain unequivocal evidence for the role of PPARgamma for Th17 differentiation, we generated T cell-specific PPARgamma knockout mice by crossing CD4-Cre mice with mice carrying loxP sites within the PPARgamma gene (CD4-PPARgammaKO; ). In the absence of PPARgamma, Th17 differentiation was strongly increased when compared with wild-type CD4+ T cells (Fig. 1 d), indicating that PPARgamma serves as a T cell-intrinsic brake of Th17 differentiation under physiological conditions. Accordingly, Th1 differentiation was not altered in CD4-PPARgammaKO T cells (Fig. 1 d). Interestingly, the endogenous PPARgamma agonist 13s-HODE, a linoleic acid derivative (Huang et al., 1999), equally suppressed Th17, but not Th1, differentiation (Fig. 1 d), further indicating that PPARgamma activity limits Th17 differentiation under physiological conditions. Given the fact that 12/15-lipoxygenase is expressed in T cells (Vanderhoek, 1988), it is reasonable to assume that endogenous ligands produced by T cells themselves serve as a brake for Th17 differentiation in an autocrine fashion. Also, PPARgamma ligand production by antigen-presenting cells may contribute to local control of Th17 differentiation (Huang et al., 1999).
###end p 6
###begin p 7
###xml 0 45 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Control of Th17 differentiation by PPAR&#947;.</bold>
###xml 112 113 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 283 284 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 397 398 393 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 535 536 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 584 589 578 583 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35-55</sub>
###xml 666 667 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 671 672 661 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 761 762 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 810 811 798 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 838 840 822 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 841 845 <span type="species:ncbi:10090">mice</span>
Control of Th17 differentiation by PPARgamma. (a) MOG-EAE was induced in PIO or vehicle-treated wild-type mice (n = 6 per group, 3 experiments), and the clinical disease score was assessed daily. (b) In a separate experiment, mice were sacrificed at the peak of disease (day 18), CD4+ T cells were isolated from the CNS, restimulated with PMA/ionomycin, and analyzed by flow cytometry gated on CD4+ T cells; representative dot plots and mean results +/- SEM from four animals per group are shown; data are from two experiments. (c) CD4+ T cells from the CNS were restimulated with MOG35-55-loaded DCs, and numbers of IL-17 and of IFN-gamma-producing cells per 3 x 104 CD4+ T cells were determined by ELISpot analysis. Graphs denote mean +/- SEM of all animals (n = 6 per group, 2 experiments). (d) Purified CD4+ T cells from CD4-PPARgammaKO mice or WT littermates were treated with PIO or the endogenous PPARgamma agonist 13s-HODE, and Th17 differentiation was induced by stimulation for 72 h (top row). Alternatively, Th1 differentiation was induced for 72 h (bottom row). Cytokine-producing cells were determined by flow cytometry after PMA/ionomycin restimulation. Only living cells were analyzed by using LIVE/DEAD stain and exclusion of autofluorescence (x axis). Numbers denote mean percentage +/- SEM. (e) Th17 differentiation was induced as above and TNF, IL-17A, and IL-22 expression were determined by flow cytometry. Numbers denote mean percentage +/- SEM. (f) Th17 differentiation was induced as above; after 72 h expression of IL-17A, IL-17F, IL-21, and IL-23R were measured by quantitative real-time RT-PCR normalized to beta-actin levels. (g) Additionally, CCR6-expression was determined by flow cytometry; CCL20-release was assessed by ELISA. (d-g) One out of at least three independent experiments is shown.
###end p 7
###begin p 8
###xml 245 253 237 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 e</xref>
###xml 306 314 298 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 f</xref>
###xml 445 453 433 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 g</xref>
We further substantiated the inhibitory effect of PPARgamma on Th17 differentiation by investigating other classical markers of Th17 cells. In addition to IL-17A, we found that PPARgamma activation by PIO suppressed expression of TNF and IL-22 (Fig. 1 e), as well as IL-17F, IL-21, and IL-23R, in T cells (Fig. 1 f). Likewise, expression of the chemokine receptor CCR6 and its ligand CCL20 were also strongly controlled by PPARgamma activation (Fig. 1 g). This demonstrates that PPARgamma, indeed, influenced differentiation of Th17 cells rather than merely suppressing IL-17A production.
###end p 8
###begin title 9
Selectivity of PPARgamma for Th17 differentiation
###end title 9
###begin p 10
###xml 145 146 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 278 279 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 380 388 373 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 a</xref>
###xml 486 499 479 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Chambon, 1994</xref>
###xml 590 609 583 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Mucida et al., 2007</xref>
###xml 765 773 755 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 a</xref>
###xml 802 804 788 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 1068 1076 1047 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 a</xref>
###xml 1112 1130 1091 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Iwata et al., 2003</xref>
To further characterize the specificity of PPARgamma on the differentiation of Th17 cells, we evaluated the effect of PIO on cytokine-induced CD4+ T cell differentiation into Th1, Th2, or regulatory T cells. Importantly, PIO did not modulate TGF-beta-mediated induction of Foxp3+ regulatory T cells, IL-4-mediated induction of Th2 cells, or IL-12-mediated induction of Th1 cells (Fig. 2 a). This is in contrast to the effect of RA, which is a natural ligand of the nuclear RA receptor (Chambon, 1994) that has been shown to reciprocally regulate Th17 and regulatory T cell differentiation (Mucida et al., 2007). In direct comparison, RA and PIO both efficiently suppressed Th17 differentiation, whereas RA but not PIO induced TGF-beta-mediated expression of Foxp3 (Fig. 2 a). Accordingly, CD4-PPARgammaKO T cells did not show altered TGF-beta-mediated Foxp3-induction (unpublished data). A further distinction between RA and PIO was observed on Th1 differentiation, as RA slightly but significantly impeded IL-12-mediated induction of IFN-gamma expression in T cells (Fig. 2 a), as has been previously reported (Iwata et al., 2003). Collectively, these data indicate that distinct molecular mechanisms were involved in PPARgamma-mediated, as compared with RA-mediated, control of T cell differentiation.
###end p 10
###begin p 11
###xml 0 50 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Selectivity of PPAR&#947; for Th17 differentiation.</bold>
###xml 58 59 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 362 363 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Selectivity of PPARgamma for Th17 differentiation. (a) CD4+ T cells were subjected to Th1, Th2, Th17, and regulatory T cell differentiation protocols, as described in the Materials and methods section, and the influence of RA and PIO on the induction of lineage markers was determined by flow cytometry and analyzed as described in Materials and methods. (b) CD4+ T cell differentiation was induced as described in Materials and methods, and the influence of PIO on expression of the lineage-determining transcription factors T-bet, GATA-3, RORgammat, and Foxp3 was determined by quantitative real-time PCR and normalized to beta-actin levels after 48 h. Data in a and b are representative of at least three independent experiments.
###end p 11
###begin p 12
###xml 112 113 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 456 464 441 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 b</xref>
###xml 746 763 723 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Zhou et al., 2008</xref>
###xml 1010 1031 983 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">Quintana et al., 2008</xref>
###xml 1033 1054 1006 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">Veldhoen et al., 2008</xref>
###xml 1199 1227 1168 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Hermann-Kleiter et al., 2008</xref>
###xml 1608 1625 1573 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Dunn et al., 2007</xref>
We next investigated whether PPARgamma also affected expression of the key transcription factors determining CD4+ T cell differentiation. PPARgamma-activation selectively suppressed TGF-beta/IL-6-mediated expression of RORgammat, the transcription factor required for Th17 induction, whereas the expression of the transcription factors determining Th1, Th2, and regulatory T cell differentiation, i.e., T-bet, GATA-3, and FoxP3, was not influenced by PIO (Fig. 2 b), again confirming that PPARgamma acted specifically on the differentiation of Th17 cells. Other transcriptional regulators have been reported to influence Th17 differentiation. Foxp3 has been shown to directly antagonize RORgammat activity, and thus prevent Th17 differentiation (Zhou et al., 2008). Furthermore, several groups have reported that the aryl hydrocarbon receptor elicits either regulatory T cell or Th17 responses when activated by distinct ligands; however, the underlying mechanisms do not seem to involve RORgammat regulation (Quintana et al., 2008; Veldhoen et al., 2008). Additionally, the nuclear orphan receptor NR2F6 seems to regulate Th17-dependent autoimmunity, but with no apparent involvement of RORgammat (Hermann-Kleiter et al., 2008). It can therefore be concluded that several receptors are involved in the T cell-intrinsic control of Th17-responses, but that the molecular pathways involved in these processes are distinct. Even among the family of PPARs, the regulatory effect on Th17 differentiation is not a general feature, as lack of PPARalpha in T cells did not result in altered IL-17 expression levels (Dunn et al., 2007).
###end p 12
###begin title 13
PPARgamma inhibits Th17 differentiation by controlling RORgammat induction
###end title 13
###begin p 14
###xml 92 94 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 185 187 165 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 197 205 177 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 a</xref>
###xml 332 334 300 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 607 627 559 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Lochner et al., 2008</xref>
###xml 724 732 673 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 b</xref>
###xml 773 776 722 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 868 883 817 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, b and c</xref>
###xml 923 924 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1151 1159 1088 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 c</xref>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
We next evaluated whether PPARgamma influenced RORgammat expression in T cells. In PPARgammaKO T cells, we observed enhanced cytokine-induced RORgammat induction compared with PPARgammaWT T cells (Fig. 3 a). The suppressive effect of PPARgamma activation by PIO on the one hand and the increased expression of RORgammat in PPARgammaKO T cells on the other hand illustrate the dynamic range of PPARgamma-mediated control of Th17 differentiation. We substantiated the influence of PPARgamma activation on RORgammat expression using reporter mice, which express GFP under control of the RORc(gammat) promoter (Lochner et al., 2008). In such T cells, we observed that PIO strongly reduced TGF-beta/IL-6-mediated GFP-expression (Fig. 3 b). Importantly, both the frequency of GFPpos T cells and the mean fluorescence intensity of GFP-expressing T cells were reduced by PIO (Fig. 3, b and c). These results indicated that most CD4+ T cells failed to express RORgammat under the influence of PPARgamma activation, thus giving rise to less Th17 cells. Furthermore, the decreased mean fluorescence intensity of GFP in PIO-treated RORc(gammat) reporter T cells (Fig. 3 c) revealed that upon PPARgamma activation there was less GFP, i.e., RORgammat, on a per cell basis, suggesting that PPARgamma reduced RORgammat transcription on a single-cell level.
###end p 14
###begin p 15
###xml 0 75 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPAR&#947; inhibits Th17 differentiation by controlling ROR&#947;t induction.</bold>
###xml 115 117 103 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 307 308 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 338 340 315 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TG</sup>
###xml 431 432 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 508 511 485 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pos</sup>
###xml 1271 1272 1222 1223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1291 1292 1242 1243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 710 716 <span type="species:ncbi:10090">murine</span>
###xml 899 905 <span type="species:ncbi:10090">murine</span>
PPARgamma inhibits Th17 differentiation by controlling RORgammat induction. (a) Th17 differentiation from PPARgammaKO and wild-type T cells was induced as described in Materials and methods; RORgammat expression was determined by quantitative real-time PCR and normalized to beta-actin levels. (b and c) CD4+ T cells from Rorc(gammat)-GFPTG reporter mice were treated with PIO, and Th17 differentiation was induced. After 14 h, GFP- expression was assessed by flow cytometry and analyzed for frequency of GFPpos cells (b) and for MFI of GFP-expressing cells (c). One out of three independent experiments is shown. (d) PPARgamma was recombinantly expressed (), and interaction of recombinant PPARgamma with the murine RORgammat promoter was determined by surface plasmon resonance analysis. Sensograms show the binding of indicated concentrations of PPARgamma at either the RORgammat promoter or the murine AP2 promoter containing a bona fide PPRE site as positive control; shown are a representative sensogram (left) and a quantitative analysis (right). The bar graph shows mean +/- SEM from three independent experiments. (e) Signal-dependent clearance of SMRT from the RORgammat promoter is prevented by PIO. ChIP experiments were performed for SMRT in mock-treated CD4+ T cells and in CD4+ T cells stimulated with TGF-beta/IL6 in the presence or absence of PIO. ChIP assay was performed with alphaSMRT or IgG for control of specificity. Immunoprecipitated DNA was analyzed by quantitative PCR using primers specific for the RORgammat promoter; as control, binding of SMRT to a nonrelated DNA control (exon 1 of the RORgamma gene) was investigated and set as 1. Two independent experiments were performed, and mean results +/- SEM are shown.
###end p 15
###begin p 16
###xml 674 695 626 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Frohnert et al., 1999</xref>
###xml 764 772 712 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 d</xref>
###xml 309 314 <span type="species:ncbi:10090">mouse</span>
The control of PPARgamma over RORgammat transcription led us to examine whether the RORgammat promoter contained a bona fide PPARgamma-binding site (PPRE), which might permit direct interaction of PPARgamma with the RORgammat promoter. Bioinformatic analysis did not reveal any known PPRE sequence within the mouse RORgammat promoter (unpublished data). In addition, we excluded direct interaction of PPARgamma with the RORgammat promoter by examining the binding of recombinant PPARgamma to the full-length RORgammat promoter using surface plasmon resonance analysis. In contrast to strong and specific binding of PPARgamma to the AP2 promoter, which contains a PPRE site (Frohnert et al., 1999), we did not observe significant binding to the RORgammat promoter (Fig. 3 d).
###end p 16
###begin p 17
###xml 424 444 404 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Pascual et al., 2005</xref>
###xml 446 468 426 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Ghisletti et al., 2009</xref>
###xml 784 785 756 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 795 803 767 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 e</xref>
###xml 854 855 826 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 967 975 932 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 e</xref>
###xml 1167 1175 1120 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 e</xref>
###xml 1480 1502 1425 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Ghisletti et al., 2009</xref>
###xml 1799 1819 1736 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Nurieva et al., 2007</xref>
###xml 1821 1839 1758 1776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Huber et al., 2008</xref>
###xml 775 780 <span type="species:ncbi:10090">mouse</span>
The lack of a high-affinity PPARgamma binding site in the RORgammat promoter raised the possibility that PPARgamma might negatively regulate RORgammat transcription through a transrepression mechanism that does not require direct DNA binding. One such mechanism involves the ability of ligand-activated PPARgamma to inhibit signal-dependent clearance of NCoR or SMRT corepressor complexes from promoters of regulated genes (Pascual et al., 2005; Ghisletti et al., 2009). To investigate this possibility, we used chromatin immunoprecipitation (ChIP) to screen of genomic sequences surrounding the RORgammat promoter (unpublished data) for corepressor binding. These studies revealed the binding of the corepressor SMRT, but not NCoR, at the RORgammat promoter in unstimulated mouse CD4+ T cells (Fig. 3 e and not depicted). Importantly, stimulation of CD4+ T cells with TGF-beta and IL-6 resulted in rapid and nearly complete loss of SMRT from the RORgammat promoter (Fig. 3 e), indicating that SMRT clearance precedes RORgammat activation. Interestingly, this cytokine-induced clearance of SMRT from the RORgammat promoter was prevented by the PPARgamma agonist PIO (Fig. 3 e). These data suggest that the retention of SMRT results in persistent repression of RORgammat in the presence of activating cytokines, and are consistent with prior studies demonstrating that PPARgamma suppresses activation of inflammatory response genes in macrophages by preventing NCoR/SMRT turnover (Ghisletti et al., 2009). Interference of SMRT clearance from the RORgammat promoter thus provides a previously unrecognized mechanism by which ligand-activated PPARgamma may control Th17 differentiation in T cells. However, these findings do not exclude other mechanisms, such as modulation of STAT3 or IRF4 signaling (Nurieva et al., 2007; Huber et al., 2008).
###end p 17
###begin title 18
PPARgamma in T cells controls CNS autoimmunity and restricts Th17 differentiation in vivo
###end title 18
###begin p 19
###xml 121 123 113 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 169 171 157 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 308 316 296 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 a</xref>
###xml 505 525 493 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Heppner et al., 2005</xref>
###xml 561 563 545 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 631 632 615 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 653 661 637 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 b</xref>
###xml 767 769 747 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 827 828 807 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1073 1081 1053 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 b</xref>
###xml 1136 1138 1112 1114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 1165 1170 1141 1146 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35-55</sub>
###xml 1208 1209 1184 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1414 1429 1390 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, b and c</xref>
###xml 1512 1513 1484 1485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1537 1545 1509 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 c</xref>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 770 774 <span type="species:ncbi:10090">mice</span>
###xml 985 989 <span type="species:ncbi:10090">mice</span>
###xml 1139 1143 <span type="species:ncbi:10090">mice</span>
###xml 1531 1535 <span type="species:ncbi:10090">mice</span>
To analyze whether PPARgamma is involved in T cell-intrinsic control of CNS autoimmunity, we induced EAE in CD4-PPARgammaKO mice and wild-type littermates. CD4-PPARgammaKO mice showed a significantly earlier onset and aggravated disease course during the initial T cell-dependent phase of disease until d15 (Fig. 4 a). However, this difference was not observed in the effector phase, when disease activity is mainly determined by a local inflammatory response within the CNS governed by microglial cells (Heppner et al., 2005). Disease activity in CD4-PPARgammaKO mice directly correlated with the total numbers of infiltrating CD4+ T cells in the CNS (Fig. 4 b). Both at the beginning of clinical disease activity (day 8), and at the peak of disease in CD4-PPARgammaKO mice (day 13), we found significantly increased total CD4+ T cell numbers in the CNS. Later (day 18) disease score and T cell influx were not different from wild-type littermates. As expected, PIO-treated wild-type mice exhibited decreased T cell numbers within the CNS at all time points investigated (Fig. 4 b). Importantly, at the peak of disease in CD4-PPARgammaKO mice, the frequency of MOG35-55 peptide-specific, IL-17-producing CD4+ T cells in the CNS was increased by threefold, which, together with the increase in T cell influx, enhanced the numbers of IL-17-producing autoreactive T cells within the target organ by nearly fivefold (Fig. 4, b and c). In contrast, there was no alteration in antigen-specific IFN-gamma-producing CD4+ T cells in these mice (Fig. 4 c).
###end p 19
###begin p 20
###xml 0 90 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPAR&#947; in T cells controls CNS autoimmunity and restricts Th17 differentiation in vivo.</bold>
###xml 131 133 123 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 156 158 144 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 172 173 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 466 467 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 560 561 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 632 637 616 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35-55</sub>
###xml 714 715 694 695 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 719 720 699 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 850 851 828 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 858 859 836 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 381 385 <span type="species:ncbi:10090">mice</span>
###xml 914 918 <span type="species:ncbi:10090">mice</span>
###xml 1003 1006 <span type="species:ncbi:31658">CFA</span>
###xml 1023 1028 <span type="species:ncbi:10090">mouse</span>
PPARgamma in T cells controls CNS autoimmunity and restricts Th17 differentiation in vivo. (a) MOG-EAE was induced in CD4-PPARgammaKO mice and CD4-PPARgammaWT littermates (n = 8 per group, 3 experiments), and the clinical disease score was assessed daily. (b) In a separate experiment, mice were sacrificed at indicated time points and mononuclear cells derived from the CNS of KO mice and WT littermates (+/- PIO) were analyzed by flow cytometry. Mean results from n = 4 animals per group and time point +/- SEM are shown; data are from 2 experiments. (c) CD4+ T cells from spleens and CNS of each animal were restimulated with MOG35-55-loaded DCs, and numbers of IL-17 and of IFN-gamma-producing cells per 3 x 104 CD4+ T cells were determined by ELISpot analysis. Graphs denote mean +/- SEM of all animals (8 per group; 3 experiments). (d and e) 106 CD90.2+ OT-II cells were adoptively transferred into congenic mice treated with PIO or vehicle alone (w/o Pio), followed by s.c. immunization with OVA/CFA (100 microg OVA/mouse). CD44 and CD62L expression levels, as well as IL-17A production upon restimulation with PMA/ionomycin, were assessed by flow cytometry at day 4. Six animals per group; shown are representative plots and mean results +/- SEM, from two experiments.
###end p 20
###begin p 21
###xml 74 76 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 314 316 302 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 323 331 311 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 c</xref>
###xml 565 585 553 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Reboldi et al., 2009</xref>
###xml 689 697 673 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 g</xref>
###xml 906 908 886 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 987 1006 967 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Chawla et al., 2001</xref>
###xml 1395 1412 1367 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">Yang et al., 2009</xref>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 812 816 <span type="species:ncbi:10090">mice</span>
###xml 909 913 <span type="species:ncbi:10090">mice</span>
The clinical symptoms and antigen-specific Th17 responses in CD4-PPARgammaKO mice both revealed that the kinetics of CNS autoimmunity in vivo were modulated by PPARgamma in a T cell-intrinsic fashion. There was pronounced accumulation of IL-17-producing T cells in the CNS compared with the spleen in CD4-PPARgammaKO mice (Fig. 4 c), which may be caused by guided entry of Th17 cells into the CNS. A recent study demonstrated that CCR6-expressing Th17 cells function as "pioneer" cells, enabling immune cell entry into the CNS at the beginning of CNS autoimmunity (Reboldi et al., 2009). In this regard, the control of expression of both CCR6 and its ligand CCL20 by PPARgamma activation (Fig. 1 g) may explain the decreased influx of T cells and the reduced disease activity in the CNS of PIO-treated wild-type mice. The protective effect of PIO on disease activity was greatly diminished in CD4-PPARgammaKO mice (), thus excluding off-target effects that had been reported previously (Chawla et al., 2001) and further demonstrating that PPARgamma expression in T cells was required for full protective effect of PIO on CNS autoimmunity. The observation that PPARgamma activation in vivo did not entirely protect from EAE development, despite its profound effect on Th17 differentiation, lends support for a key but not exclusive role of Th17 cells in CNS inflammation, as previously reported (Yang et al., 2009). The persistent Th1 responses, which were not altered by PPARgamma activation, may explain persistent disease activity, despite diminished Th17 responses.
###end p 21
###begin p 22
###xml 111 113 107 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 143 151 139 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 c</xref>
###xml 293 294 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 298 299 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 471 479 463 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 d</xref>
###xml 503 511 495 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 e</xref>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 362 365 <span type="species:ncbi:31658">CFA</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
As we also observed a significant increase in antigen-specific Th17 cell numbers in the spleen in CD4-PPARgammaKO mice at the peak of disease (Fig. 4 c), we next asked whether PPARgamma influenced Th17 differentiation in vivo at early time points. To this end, we adoptively transferred CD90.2+ CD4+ T cells from OT-II mice, followed by immunization with OVA in CFA. Importantly, PIO treatment of these mice strongly interfered with the expression of activation markers (Fig. 4 d) and IL-17 production (Fig. 4 e) by the adoptively transferred T cells 4 d after immunization; this persisted for longer than 4 d (day 7; not depicted), demonstrating that PPARgamma controls antigen-specific Th17 differentiation in vivo.
###end p 22
###begin p 23
###xml 260 262 244 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
Collectively, the entire range of PPARgamma-sensitive control of Th17 differentiation in vivo and CNS autoimmunity is reflected by the combination of pharmacological PPARgamma activation on the one hand and by the absence of PPARgamma-activity in CD4-PPARgammaKO mice on the other hand.
###end p 23
###begin title 24
###xml 98 106 <span type="species:ncbi:9606">patients</span>
PPARgamma selectively controls Th17 differentiation in T cells from healthy controls (HCs) and MS patients
###end title 24
###begin p 25
###xml 462 463 443 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 467 468 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 505 513 486 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 a</xref>
###xml 757 765 738 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 b</xref>
###xml 840 848 817 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 b</xref>
###xml 1032 1040 1005 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 c</xref>
###xml 1130 1131 1099 1100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1274 1282 1239 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 d</xref>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 1121 1126 <span type="species:ncbi:9606">human</span>
The protective effects of PPARgamma on both clinical manifestation and Th17-responses during EAE prompted us to investigate whether T cells from HCs and MS patients were susceptible to treatment with PPARgamma agonists. Again, we focused on the effect of PPARgamma activation on T cells by using direct stimulation with TGF-beta/IL-21 in the absence of antigen-presenting cells. Pharmacologic PPARgamma activation reduced the frequency of IL-17A-producing CD45RA+ CD4+ T cells both in HC and MS patients (Fig. 5 a). Although in our experiments there was no apparent difference in Th17 differentiation between HC and MS patients in vitro, it is important to note that PIO-treatment was equally effective in potent suppression of IL-17A release from T cells (Fig. 5 b). Moreover, no influence of PIO was observed during IFN-gamma production (Fig. 5 b). Pharmacologic PPARgamma activation prevented Th17 differentiation, as demonstrated by diminished expression of the Th17 markers IL-17F, IL-21, IL-22, and IL-23R upon PIO treatment (Fig. 5 c). Importantly, the specific effect of PPARgamma activation on Th17 induction in human CD4+ T cells was further illustrated by selective regulation of RORgammat expression, whereas T-bet and GATA-3 expression were not altered by PIO (Fig. 5 d).
###end p 25
###begin p 26
###xml 0 88 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPAR&#947; selectively controls Th17 differentiation in T cells from HCs and MS patients.</bold>
###xml 95 96 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 100 101 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 119 120 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 167 168 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 260 261 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 493 494 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 508 509 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 666 667 653 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 158 165 <span type="species:ncbi:9606">patient</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
PPARgamma selectively controls Th17 differentiation in T cells from HCs and MS patients. CD45RA+ CD4+ T cells from HC (n = 5) and from relapsing-remitting MS patient (n = 7) were treated with PIO and stimulated as described in Materials and methods. (a) IL-17A+ cells from HC and MS-patients after restimulation with PMA/ionomycin were assessed by flow cytometry. (b) IL-17A and IFN-gamma secretion were determined by ELISA. Graphs show mean percentages +/- SEM from the separate experiments (n = 7). (c) CD4+ T cells were activated as in a, and expression of IL-17F, IL-21, IL-22, and IL-23R was measured by real-time RT-PCR normalized to beta-actin levels. (d) CD4+ T cells were stimulated as described, and expression of RORgammat, T-bet, and GATA-3 after 72 h was measured by real-time PCR and normalized to beta-actin levels. (c and d) One representative dataset out of three is shown.
###end p 26
###begin p 27
In summary, we identify PPARgamma as a defined molecular target to selectively modulate Th17 differentiation in a T cell-intrinsic fashion, which opens up new possibilities for specific immunointervention in Th17-mediated autoimmune diseases such as MS.
###end p 27
###begin title 28
MATERIALS AND METHODS
###end title 28
###begin title 29

###end title 29
###begin title 30
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 30
###begin p 31
###xml 64 69 56 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 77 80 69 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 101 103 89 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 146 151 130 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 158 173 142 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">He et al., 2003</xref>
###xml 187 190 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 287 303 271 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Lee et al., 2001</xref>
###xml 613 614 589 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 673 680 649 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 713 715 685 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TG</sup>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 191 206 <span type="species:ncbi:10090">transgenic mice</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 734 738 <span type="species:ncbi:10090">mice</span>
CD4-specific PPARgamma knockout mice with the genotype PPARgammafl/fl CD4-Cre+/- (i.e., CD4-PPARgammaKO mice) were generated by crossing PPARgammafl/fl mice (He et al., 2003) with CD4-Cre+/- transgenic mice expressing Cre recombinase under control of the CD4 enhancer/promoter/silencer (Lee et al., 2001). Expression of Cre recombinase in CD4-expressing T cells leads to recombination at two loxP sites flanking exons two and three of the PPARgamma gene, thus resulting in a T cell-specific PPARgamma knockout (Fig. S1). We did not observe any alteration in immune cell frequencies in these mice (Fig. S1). CD90.2+ CD4-TCR transgenic OT II mice specific for the peptide ova323-339, BAC-transgenic Rorc(gammat)-GFPTG mice, and C57BL/6 mice (Charles River Laboratories) were maintained under specific pathogen-free conditions. All animal experiments were performed according to the guidelines of the animal ethics committee and were approved by the government authorities of Nordrhein-Westfalen, Germany.
###end p 31
###begin title 32
Cell culture and adoptive cell transfer.
###end title 32
###begin p 33
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 219 220 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 226 227 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 559 576 540 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">Yang et al., 2008</xref>
###xml 657 658 634 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1246 1253 1197 1204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">323-339</sub>
###xml 1444 1445 1383 1384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1503 1504 1442 1443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1525 1526 1464 1465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1624 1625 1559 1560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 640 645 <span type="species:ncbi:10090">Mouse</span>
###xml 1168 1172 <span type="species:ncbi:10090">mice</span>
###xml 1464 1468 <span type="species:ncbi:10090">mice</span>
###xml 1635 1639 <span type="species:ncbi:10090">mice</span>
PBMCs were obtained from the peripheral blood of healthy volunteers or from patients with clinically definite relapsing-remitting MS according to the McDonald criteria, approved by the local Ethics Committee. CD4+CD45RA+CD45RO-CD25- T cells were isolated by immunomagnetic cell separation using an AutoMACS (Miltenyi Biotec) and stimulated with plate-bound 1.5 microg/ml alphaCD3 antibody (OKT3), 1 microg/ml alphaCD28 antibody (28.2), 2.5 ng/ml TGF-beta (R&D Systems) and 12.5 ng/ml IL-21 (Cell Systems) for 7 d in serum-free X-VIVO 15 medium (Biowhittaker; Yang et al., 2008). 10 microM PIO (Enzo Biochem, Inc.) was added when indicated. Mouse splenic CD4+ T cells were isolated by immunomagnetic separation using CD4-MACS beads (Miltenyi Biotec) and stimulated with plate-bound 4 microg/ml alphaCD3 antibody (145-2C11) and 4 microg/ml alphaCD28 antibody (3751) together with 5 ng/ml TGF-beta and 20 ng/ml IL-6 (PeproTech) for Th17 differentiation; with IL-12 (10 ng/ml) for Th1 differentiation; with IL-4 (10 ng/ml) for Th2 differentiation or with TGF-beta alone (5 ng/ml) for regulatory T cell differentiation. In one experiment, MACS-isolated splenic DCs from B6 mice were cocultured with T cells in the presence of antigen (10 microg/ml ova323-339). The endogenous PPARgamma agonist 13s-HODE (Cayman Chemicals) was used at a concentration of 10 microM. All-trans RA (Sigma-Aldrich) was used at a 1 microM concentration. TCR transgenic CD4+ T cells from OTII mice bearing the congenic marker CD90.1+ were isolated and 106 cells were adoptively transferred by bolus i.v. injection in 200 microl PBS into wild-type CD90.2+ congenic mice.
###end p 33
###begin title 34
EAE.
###end title 34
###begin p 35
###xml 47 52 43 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35-55</sub>
###xml 128 154 124 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 188 214 184 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bordetella pertussis toxin</italic>
###xml 86 89 <span type="species:ncbi:31658">CFA</span>
###xml 128 154 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 188 208 <span type="species:ncbi:520">Bordetella pertussis</span>
EAE was induced by s.c. injecting 50 microg MOG35-55 peptide (BIOTREND) emulsified in CFA (Difco) with 8 mg/ml heat-inactivated Mycobacterium tuberculosis and two i.p. injections of 200ng Bordetella pertussis toxin (List Biologicals) on days 0 and 2. Clinical assessment of EAE was performed daily using a scale ranging from 0 to 6: 0, clinically normal; 1, reduced tone of tail; 2, ataxia and/or slight hind-limb paresis; 3, severe hind-limb paresis; 4, hind limb plegia; 5, tetraparesis; 6, moribund/dead animals. Cell analysis from spleens and CNS was performed as indicated.
###end p 35
###begin title 36
Real-time RT-PCR.
###end title 36
###begin p 37
Cells were washed with ice-cold PBS, and RNA extraction was performed using the RNeasy mini kit (QIAGEN) according to the manufacturer's protocol. Reverse transcription of RNA was performed with SuperScript III (Invitrogen). cDNA was analyzed using FAM-labeled TaqMan probes obtained from Applied Biosystems and used according to the manufacturer's recommendations. mRNA expression levels of RORgammat, T-bet, GATA-3, and Foxp3, as well as the Th17 markers IL-17A, IL17F, IL-21, IL-22, and IL-23R, were assessed using gene-specific primers. Gene expression was assessed in triplicates and normalized to beta-actin. Amplification of cDNA was performed on an AbiPrism 7900 HT cycler (Applied Biosystems).
###end p 37
###begin title 38
Cytokine detection.
###end title 38
###begin p 39
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 347 352 <span type="species:ncbi:9606">Human</span>
Mouse IL-17A and Foxp3 protein expression were examined by intracellular staining according to the manufacturer's protocol. MOG-specific IL-17 and IFN-gamma production was analyzed by specific ELISpot assays according to the manufacturer's procedures (R&D Systems), and spot numbers were counted with an automated ELISpot reader (BIOREADER-2000). Human IL-17A and IFN-gamma protein levels from cell culture supernatants were determined by ELISA (R&D Systems).
###end p 39
###begin title 40
ChIP experiments.
###end title 40
###begin p 41
###xml 52 72 52 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Pascual et al., 2005</xref>
###xml 321 330 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 219 225 <span type="species:ncbi:9986">rabbit</span>
ChIP assays were performed as previously described (Pascual et al., 2005). Th17 differentiation was induced for the indicated time points before cross-linking for 10 min with 1% formaldehyde. Anti-SMRT (ABR) or control rabbit IgG (Santa Cruz Biotechnology, Inc.) were used for immunoprecipitation. A 150-bp region of the RORgammat promoter was amplified spanning the most proximal transcription start site. Quantitative PCR was performed with SYBR-GreenER (Invitrogen) and analyzed on a 7200 real time PCR system (ABI).
###end p 41
###begin title 42
Surface plasmon resonance analysis.
###end title 42
###begin p 43
###xml 68 84 64 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 68 89 <span type="species:ncbi:511693">Escherichia coli BL21</span>
###xml 184 189 <span type="species:ncbi:10090">mouse</span>
###xml 204 209 <span type="species:ncbi:10090">mouse</span>
###xml 524 529 <span type="species:ncbi:10090">mouse</span>
###xml 863 868 <span type="species:ncbi:10090">mouse</span>
6xHIS-PPARgamma was recombinantly expressed in the bacterial strain Escherichia coli BL21, eluted, and desalted using a PD-10 column and 10% glycerol in PBS. The promoter sequences of mouse RORgammat and mouse AP2 were amplified by PCR using the oligonucleotides (5'-GCTTCCCAATGGACACTTGCAAG-3' and 5'-AGGACAGCACACAGCTGGCAGTGG-3' for RORgammat; and 5'-TCTAGAAGGAAGAACCAGGG-3' and 5'-AGGCAGAAATGCACATTTCACC-3' for AP2). For each reaction, one primer was biotinylated at the 5' end. As negative control, a 2-kb fragment of the mouse mannose receptor was amplified. For SPR analysis of promotor binding, a Biacore 3000 (GE Healthcare) was used. In brief, 700-1,000 RU of 5'-biotinylated variants of the respective dsDNAs were immobilized on the surface of a SA-sensorchip (GE Healthcare) according to the manufacturer's instructions. As negative control, 2 kb of the mouse mannose receptor was used. PBS (pH 7.3) was used as running buffer, and the regeneration of the surface was accomplished by injecting 1 M Urea for 30 s. All measurements were done at a flow rate of 30 microl/min, and protein injections at indicated concentrations were conducted for 2 min using the "inject" mode. Measurements were done in the presence of 0.001 mg/ml heparin to reduce unspecific binding.
###end p 43
###begin title 44
Online supplemental material.
###end title 44
###begin p 45
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 609 611 585 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sup>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 268 274 <span type="species:ncbi:10090">murine</span>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows the Th17 differentation of highly purified naive CD4+ T cells. Fig. S2 shows the generation of T cell-specific PPARgamma knockout mice and phenotypic characterization of immune cells. Fig. S3 shows the purification of recombinantly expressed full-length murine PPARgamma; surface plasmon resonance analysis of PPARgamma-binding to PPRE-oligonucleotides; and effect of PPARgamma on SMRT-binding to the RORgammat promoter in the absence of Th17 inducing conditions. Fig. S4 shows the effect of the CD4-Cre transgene on EAE disease course and the absence of a protective PIO effect in CD4-PPARgammaKO mice. Online supplemental material is available at .
###end p 45
###begin title 46
Supplementary Material
###end title 46
###begin title 47
[Supplemental Material]
###end title 47
###begin p 48
We would like to acknowledge the excellent technical assistance of N. Kuhn, C. Mandel, J. Collier, and J. Birke. Moreover, we acknowledge the assistance of the Flow Cytometry Core Facility at the Institute of Molecular Medicine and Experimental Immunology, University of Bonn, supported in part by SFB 704. We also acknowledge F. Frommer in helping to establish EAE-models.
###end p 48
###begin p 49
This work was funded by SFB 704, BONFOR, KFO 177.
###end p 49
###begin p 50
The authors have no conflicting financial interest.
###end p 50
###begin article-title 51
Th17: the third member of the effector T cell trilogy.
###end article-title 51
###begin article-title 52
The retinoid signaling pathway: molecular and genetic analyses.
###end article-title 52
###begin article-title 53
PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation.
###end article-title 53
###begin article-title 54
The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses.
###end article-title 54
###begin article-title 55
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.
###end article-title 55
###begin article-title 56
Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis.
###end article-title 56
###begin article-title 57
Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity.
###end article-title 57
###begin article-title 58
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
###end article-title 58
###begin article-title 59
###xml 81 87 <span type="species:ncbi:10090">murine</span>
Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene.
###end article-title 59
###begin article-title 60
Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways.
###end article-title 60
###begin article-title 61
Combinatorial roles of nuclear receptors in inflammation and immunity.
###end article-title 61
###begin article-title 62
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.
###end article-title 62
###begin article-title 63
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.
###end article-title 63
###begin article-title 64
Experimental autoimmune encephalomyelitis repressed by microglial paralysis.
###end article-title 64
###begin article-title 65
The nuclear orphan receptor NR2F6 suppresses lymphocyte activation and T helper 17-dependent autoimmunity.
###end article-title 65
###begin article-title 66
Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase.
###end article-title 66
###begin article-title 67
IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype.
###end article-title 67
###begin article-title 68
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.
###end article-title 68
###begin article-title 69
Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors.
###end article-title 69
###begin article-title 70
Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy.
###end article-title 70
###begin article-title 71
A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival.
###end article-title 71
###begin article-title 72
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 84 85 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgammat+ T cells.
###end article-title 72
###begin article-title 73
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.
###end article-title 73
###begin article-title 74
###xml 23 28 <span type="species:ncbi:9606">human</span>
The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat.
###end article-title 74
###begin article-title 75
Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid.
###end article-title 75
###begin article-title 76
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
###end article-title 76
###begin article-title 77
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma.
###end article-title 77
###begin article-title 78
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.
###end article-title 78
###begin article-title 79
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.
###end article-title 79
###begin article-title 80
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma.
###end article-title 80
###begin article-title 81
Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor.
###end article-title 81
###begin article-title 82
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE.
###end article-title 82
###begin article-title 83
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.
###end article-title 83
###begin article-title 84
###xml 36 41 <span type="species:ncbi:9606">human</span>
PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism.
###end article-title 84
###begin article-title 85
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.
###end article-title 85
###begin article-title 86
Role of the 15-lipoxygenase in the immune system.
###end article-title 86
###begin article-title 87
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins.
###end article-title 87
###begin article-title 88
###xml 55 60 <span type="species:ncbi:9606">human</span>
IL-21 and TGF-beta are required for differentiation of human T(H)17 cells.
###end article-title 88
###begin article-title 89
T-bet is essential for encephalitogenicity of both Th1 and Th17 cells.
###end article-title 89
###begin article-title 90
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.
###end article-title 90
###begin article-title 91
TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.
###end article-title 91
###begin p 92
###xml 0 19 0 19 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="93">Abbreviations used:</title>
###xml 19 23 19 23 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ChIP</term>
###xml 23 52 23 52 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="94">chromatin immunoprecipitation</p>
###xml 23 52 23 52 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="94">chromatin immunoprecipitation</p></def>
###xml 19 52 19 52 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>ChIP</term><def><p textid="94">chromatin immunoprecipitation</p></def></def-item>
###xml 52 55 52 55 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNS</term>
###xml 55 77 55 77 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="95">central nervous system</p>
###xml 55 77 55 77 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="95">central nervous system</p></def>
###xml 52 77 52 77 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>CNS</term><def><p textid="95">central nervous system</p></def></def-item>
###xml 77 80 77 80 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EAE</term>
###xml 80 121 80 121 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="96">experimental autoimmune encephalomyelitis</p>
###xml 80 121 80 121 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="96">experimental autoimmune encephalomyelitis</p></def>
###xml 77 121 77 121 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>EAE</term><def><p textid="96">experimental autoimmune encephalomyelitis</p></def></def-item>
###xml 121 123 121 123 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HC</term>
###xml 123 138 123 138 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="97">healthy control</p>
###xml 123 138 123 138 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="97">healthy control</p></def>
###xml 121 138 121 138 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>HC</term><def><p textid="97">healthy control</p></def></def-item>
###xml 138 142 138 142 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HODE</term>
###xml 142 169 142 169 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="98">hydroxyoctadecadienoic acid</p>
###xml 142 169 142 169 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="98">hydroxyoctadecadienoic acid</p></def>
###xml 138 169 138 169 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>HODE</term><def><p textid="98">hydroxyoctadecadienoic acid</p></def></def-item>
###xml 169 171 169 171 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MS</term>
###xml 171 189 171 189 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="99">multiple sclerosis</p>
###xml 171 189 171 189 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="99">multiple sclerosis</p></def>
###xml 169 189 169 189 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>MS</term><def><p textid="99">multiple sclerosis</p></def></def-item>
###xml 189 193 189 193 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NCoR</term>
###xml 193 212 193 212 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="100">nuclear corepressor</p>
###xml 193 212 193 212 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="100">nuclear corepressor</p></def>
###xml 189 212 189 212 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>NCoR</term><def><p textid="100">nuclear corepressor</p></def></def-item>
###xml 212 215 212 215 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIO</term>
###xml 215 227 215 227 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="101">pioglitazone</p>
###xml 215 227 215 227 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="101">pioglitazone</p></def>
###xml 212 227 212 227 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>PIO</term><def><p textid="101">pioglitazone</p></def></def-item>
###xml 227 237 227 233 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPAR &#947;</term>
###xml 237 285 233 277 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="102">peroxisome proliferator&#8211;activated receptor &#947;</p>
###xml 237 285 233 277 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="102">peroxisome proliferator&#8211;activated receptor &#947;</p></def>
###xml 227 285 227 277 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>PPAR &#947;</term><def><p textid="102">peroxisome proliferator&#8211;activated receptor &#947;</p></def></def-item>
###xml 285 289 277 281 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPRE</term>
###xml 289 310 281 302 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="103">PPAR response element</p>
###xml 289 310 281 302 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="103">PPAR response element</p></def>
###xml 285 310 277 302 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>PPRE</term><def><p textid="103">PPAR response element</p></def></def-item>
###xml 310 312 302 304 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RA</term>
###xml 312 325 304 317 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="104">retinoic acid</p>
###xml 312 325 304 317 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="104">retinoic acid</p></def>
###xml 310 325 302 317 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>RA</term><def><p textid="104">retinoic acid</p></def></def-item>
###xml 325 334 317 322 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</term>
###xml 334 376 322 360 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="105">RA receptor&#8211;related orphan receptor &#947;t</p>
###xml 334 376 322 360 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="105">RA receptor&#8211;related orphan receptor &#947;t</p></def>
###xml 325 376 317 360 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>ROR&#947;t</term><def><p textid="105">RA receptor&#8211;related orphan receptor &#947;t</p></def></def-item>
###xml 376 380 360 364 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMRT</term>
###xml 380 441 364 425 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="106">silencing mediator for retinoid and thyroid hormone receptors</p>
###xml 380 441 364 425 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="106">silencing mediator for retinoid and thyroid hormone receptors</p></def>
###xml 376 441 360 425 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>SMRT</term><def><p textid="106">silencing mediator for retinoid and thyroid hormone receptors</p></def></def-item>
###xml 0 441 0 425 <def-list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="93">Abbreviations used:</title><def-item><term>ChIP</term><def><p textid="94">chromatin immunoprecipitation</p></def></def-item><def-item><term>CNS</term><def><p textid="95">central nervous system</p></def></def-item><def-item><term>EAE</term><def><p textid="96">experimental autoimmune encephalomyelitis</p></def></def-item><def-item><term>HC</term><def><p textid="97">healthy control</p></def></def-item><def-item><term>HODE</term><def><p textid="98">hydroxyoctadecadienoic acid</p></def></def-item><def-item><term>MS</term><def><p textid="99">multiple sclerosis</p></def></def-item><def-item><term>NCoR</term><def><p textid="100">nuclear corepressor</p></def></def-item><def-item><term>PIO</term><def><p textid="101">pioglitazone</p></def></def-item><def-item><term>PPAR &#947;</term><def><p textid="102">peroxisome proliferator&#8211;activated receptor &#947;</p></def></def-item><def-item><term>PPRE</term><def><p textid="103">PPAR response element</p></def></def-item><def-item><term>RA</term><def><p textid="104">retinoic acid</p></def></def-item><def-item><term>ROR&#947;t</term><def><p textid="105">RA receptor&#8211;related orphan receptor &#947;t</p></def></def-item><def-item><term>SMRT</term><def><p textid="106">silencing mediator for retinoid and thyroid hormone receptors</p></def></def-item></def-list>
Abbreviations used:ChIPchromatin immunoprecipitationCNScentral nervous systemEAEexperimental autoimmune encephalomyelitisHChealthy controlHODEhydroxyoctadecadienoic acidMSmultiple sclerosisNCoRnuclear corepressorPIOpioglitazonePPAR gammaperoxisome proliferator-activated receptor gammaPPREPPAR response elementRAretinoic acidRORgammatRA receptor-related orphan receptor gammatSMRTsilencing mediator for retinoid and thyroid hormone receptors
###end p 92
###begin title 93
Abbreviations used:
###end title 93
###begin p 94
chromatin immunoprecipitation
###end p 94
###begin p 95
central nervous system
###end p 95
###begin p 96
experimental autoimmune encephalomyelitis
###end p 96
###begin p 97
healthy control
###end p 97
###begin p 98
hydroxyoctadecadienoic acid
###end p 98
###begin p 99
multiple sclerosis
###end p 99
###begin p 100
nuclear corepressor
###end p 100
###begin p 101
pioglitazone
###end p 101
###begin p 102
peroxisome proliferator-activated receptor gamma
###end p 102
###begin p 103
PPAR response element
###end p 103
###begin p 104
retinoic acid
###end p 104
###begin p 105
RA receptor-related orphan receptor gammat
###end p 105
###begin p 106
silencing mediator for retinoid and thyroid hormone receptors
###end p 106

